Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
AstraZeneca
Seagen Inc.
Mayo Clinic
Mayo Clinic
Kivu Bioscience Inc.
MediLink Therapeutics (Suzhou) Co., Ltd.
Convalife (Shanghai) Co., Ltd.
Neonc Technologies, Inc.
ViroMissile, Inc.
Arcus Biosciences, Inc.
Bristol-Myers Squibb
Sichuan Enray Pharmaceutical Sciences Company
AstraZeneca
AstraZeneca
Tizona Therapeutics, Inc
Eli Lilly and Company
University of Colorado, Denver
MacroGenics
Karolinska University Hospital
SystImmune Inc.
Pheon Therapeutics
Daiichi Sankyo
Eli Lilly and Company
Adela, Inc
Orano Med LLC
Radiopharm Theranostics, Ltd
ImmunityBio, Inc.
Eli Lilly and Company
Ocellaris Pharma, Inc.
Medical College of Wisconsin
Innate Pharma
Mayo Clinic
Tanabe Pharma America, Inc.
CRISPR Therapeutics
Radiopharm Theranostics, Ltd
HiFiBiO Therapeutics
DualityBio Inc.
TScan Therapeutics, Inc.
University of Pittsburgh
Massive Bio, Inc.
Rondo Therapeutics
Incyte Corporation
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
University of Arizona
Chongqing Precision Biotech Co., Ltd
LigaChem Biosciences, Inc.
Merck Sharp & Dohme LLC